自查补税超5000万元、审计师更换，信邦制药接连公告

Group 1: Financial Impact - The company announced a tax payment and late fees totaling 50.79 million yuan, which will be recorded in the 2025 financial results, directly affecting annual profits [1] - For the first three quarters of 2025, the company reported revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [1] Group 2: Audit Changes - The signing auditor for the 2025 annual audit has changed from Yu Yongchun to Xu Ruixing due to the former's departure, with the project partner being Wang Xiaoming and the quality control reviewer being Huang Haiyang [2] - The company stated that the transition of audit responsibilities has been orderly and is not expected to impact the audit process [2] Group 3: Legal Risks - The company is facing legal risks as it has been prosecuted for alleged unit bribery, with the prosecution materials received from the supervisory committee [3] - The company's subsidiary, Guizhou Keke Pharmaceutical Co., Ltd., which is 99.9964% owned by the company, has been implicated in the bribery case, with its 2023 revenue at approximately 2.278 billion yuan, net profit at 94.5 million yuan, and net assets around 2.482 billion yuan [3]